Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 4/20 | 0.36 |
| ▸ | GRM5 | P41594 | 3/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172191 | 0.74 | ALDH1A1 (1.00) | ALDH1A1KDM4EKMOCREBBPLMNA | |
| SCHEMBL10884762 | 0.73 | KMO (0.50) | ALDH1A1KDM4EKMOGRM5LMNA | |
| SCHEMBL15337050 | 0.72 | KMO (0.51) | ALDH1A1KDM4EKMOGRM5CREBBP | |
| SCHEMBL5074233 | 0.72 | KMO (0.39) | ALDH1A1KDM4EKMOGRM5LMNA | |
| SCHEMBL5512753 | 0.72 | KMO (0.39) | ALDH1A1KDM4EKMOGRM5LMNA | |
| SCHEMBL823908 | 0.71 | ALDH1A1 (0.78) | ALDH1A1KDM4EKMOGSK3BCREBBP | |
| SCHEMBL13907998 | 0.71 | KDM4E (0.43) | ALDH1A1KDM4EGRM5CREBBPNOS3 | |
| SCHEMBL15319641 | 0.70 | KMO (0.47) | ALDH1A1KDM4EKMOGRM5LMNA | |
| SCHEMBL5547925 | 0.70 | KMO (0.47) | ALDH1A1KDM4EKMOGRM5LMNA | |
| SCHEMBL5547929 | 0.70 | NOS1 (0.49) | KDM4EKMOGRM5LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381598-A4 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-03-19 | — | — | EP | disclosed |
| US-7223757-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223757-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223757-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7081454-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2006-07-25 | — | — | US | disclosed |
| US-20060079518-A1 | Novel tyrosine kinase inhibitors | WITTMAN MARK D | 2006-04-13 | — | — | US | disclosed |
| EP-1545543-A2 | NOVEL TYROSINE KINASES INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-29 | — | — | EP | disclosed |
| CN-1514833-A | Novel tyrosine kinase inhibitors | ����˹�ж�-����˹˹������˾ | 2004-07-21 | — | — | CN | disclosed |
| WO-2004031401-A2 | NOVEL TYROSINE KINASES INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-04 | — | — | US | disclosed |
| EP-1381598-A1 | NOVEL TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-01-21 | — | — | EP | disclosed |
| WO-2002079192-A1 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | ABL1, YES1, FER | ALDH1A1 1038/4885KDM4E 1067/4885KMO 1739/4885 |
| US-20060079518-A1 | Novel tyrosine kinase inhibitors | ABL1, FER, ERBB2 | ALDH1A1 1282/4885KDM4E 991/4885KMO 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.